- Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
- Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
- Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
- Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
- Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
- Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
- Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
- Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
Everest Medicines Ltd (6HN:BER) closed at 2.30, 39.09% above the 52 week low of 1.65 set on Mar 15, 2022.
1.65Mar 15 20228.35Jun 28 2021
Markit short selling activity
|Market cap||5.76bn HKD|
|EPS (TTM)||-4.06 |
Data delayed at least 15 minutes, as of May 25 2022 19:38 BST.